Abstract 4312
Background
OS and PFS are commonly correlated with response upon RECIST criteria. Whether a more dynamic approach considering overall and individual lesions trajectories may be of predictive/prognostic value is worth investigating.
Methods
Target lesions size (TL) from AXIS trial (NCT00678392: axitinib (A) vs sorafenib (S)) at baseline (bslTL) and subsequent time-points up to 24 months were retrospectively analyzed. TL were grouped by major organs. Relationship between OS/PFS and TL was assessed using mean-trajectories and joint-models (JM) with Cox/Weibull regression (C/W-R) including time to treatment interaction, with/without non-linear term. Mean trajectories obtained from unsupervised longitudinal clustering (ULC) were subject to C/W-R including S/A effect, age and IMDC risk group.
Results
Among 713 eligible pts (A:359, S:354), overall TL trajectories of A and S did not differ for the 1st 12 months, whereas individual TL trajectories strongly varied with TL localization: largest difference between A and S were observed for bone and liver, no difference for lungs. Upon ULC, 3 clusters exhibiting different patterns were characterized, cl1: bslTL ≈ 50mm not time-varying, cl2: bslTL ≈ 150mm + decreasing rate = 5mm/month and cl3: bslTL ≈ 250mm + decreasing rate = 15mm/month. Surprisingly, cluster 3 exhibited the better PFS: HR = 0.51 (0.31-0.82) and OS: HR = 0.54 (0.29-1.02). Upon JM, PFS and OS were associated with TL trajectories, respectively p = 0.0004 and p
Conclusions
Unlike overall TL, individual TL different trajectories were exhibited by A and S. Our model identified 3 clusters with different predictive and prognostic characteristics.
Clinical trial identification
Legal entity responsible for the study
ARTIC
Funding
ARTIC
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract